Ortin Laboratories Peer Comparison

NSE: ORTINGLOBE | BSE: 539287

₹15.30

₹0.37 (2.48%)

As on 31-Aug-2026IST

Market cap

₹12 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

P/B Ratio

13.7

Div. Yield

0 %

Edit

	Ortin Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	12	30,606	30,088	28,551	25,816
Revenue (₹ Cr)	0	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-0.90	414.00	288.22	-371.81	387.35
Net Margin (%)	-257.14	11.23	14.79	-3.93	26.01
RoE (%)	-70.98	8.38	29.77	-3.85	25.18
Price to Earnings	--	74.83	104.39	--	66.84
Price-To-Book	13.67	6.08	22.41	3.57	14.93

Income Statement (₹ Cr)

	Ortin Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	0.35	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	0.35	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	1.24	2,792.00	1,485.56	8,195.15	919.25
EBITDA	-0.89	772.00	450.24	1,010.13	542.56
Depreciation	0.00	226.00	50.83	857.51	37.68
EBIT	-0.89	546.00	399.41	152.62	504.88
Interest	0.00	217.00	40.84	342.73	3.77
Other Income	0.00	122.00	12.78	244.31	27.45
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	-0.89	463.00	371.35	-162.68	528.56
Provision for Tax	0.01	49.00	83.14	209.13	141.21
Profit after Tax	-0.90	414.00	288.22	-371.81	387.35

	Ortin Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	1.24	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	1.01	1,712.00	202.03	5,044.14	42.40
Current Liabilities	2.41	1,622.00	835.87	4,758.28	230.82
Total Liabilities	3.78	8,100.00	1,451.43	15,513.53	1,549.26

	Ortin Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	0.05	5,343.00	519.60	10,211.52	1,026.85
Current Assets	3.84	2,606.00	1,681.81	7,191.66	881.27
Total Assets	3.78	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	0.25	1,859.00	393.17	4,720.27	8.18
Net Current Assets	1.43	984.00	845.94	2,433.38	650.46
Contingent Liabilities	24.34	770.26	12.25	99.76	15.38

	Ortin Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-0.41	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	0.00	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	0.33	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	-0.09	-396.00	54.56	-25.99	155.52

	Ortin Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-24.36	4.07	26.97	6.61	20.14
ROE (%)	-70.98	8.38	29.77	-3.85	25.18
ROA (%)	-21.35	4.94	24.77	-2.21	21.93
EBIT Margin (%)	-254.86	15.32	20.63	1.66	34.54
Net Margin (%)	-257.14	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	-243.92	0.00	0.00	0.00	0.00

	Ortin Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	37.80	18.37	46.65	0.78	40.90
EBIT Growth (%)	2.73	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	2.17	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	4.27	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	-29.97	29.77	42.49	2.28	94.96

	Ortin Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	-13.72	76.81	102.79	-91.24	66.84
Price / Book Value	13.67	6.08	22.41	3.57	14.93
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.08
EV/EBITDA	-13.71	41.54	66.63	32.36	47.22
Market Cap (₹ Cr)	8.12	23,064.69	0.00	29,731.27	19,988.69

	Ortin Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.81	0.31	0.11	0.53	0.01
Short term debt to equity ratio	--	0.11	0.54	0.12	0.02
Current Ratio	1.60	1.61	2.01	1.51	3.82
Quick Ratio	1.60	1.06	1.14	0.87	2.82
Interest Coverage	-892.00	3.13	10.09	0.53	141.16

	Ortin Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	57.43	16.50	26.28	23.44	24.80
Asset Turnover	0.08	0.43	1.66	0.55	0.83
Receivable days	1,081.40	60.36	47.59	77.05	90.06
Inventory Days	37.33	64.42	62.58	77.13	61.02
Payable days	102.48	218.94	228.78	173.49	96.06
Cash Conversion Cycle	1,016.26	-94.15	-118.62	-19.30	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.